Cargando…

Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice

INTRODUCTION: Schizotypal disorder is associated with a high level of disability at an individual level and high societal costs. However, clinical recommendations for the treatment of schizotypal disorder are scarce and based on limited evidence. This review aims to synthesise the current evidence o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gundersen, Kristina Ballestad, Rasmussen, Andreas Rosén, Sandström, Katharina Oravsky, Albert, Nikolai, Polari, Andrea, Ebdrup, Bjørn H, Nelson, Barnaby, Glenthøj, Louise Birkedal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660957/
https://www.ncbi.nlm.nih.gov/pubmed/37977859
http://dx.doi.org/10.1136/bmjopen-2023-075140
_version_ 1785148444182052864
author Gundersen, Kristina Ballestad
Rasmussen, Andreas Rosén
Sandström, Katharina Oravsky
Albert, Nikolai
Polari, Andrea
Ebdrup, Bjørn H
Nelson, Barnaby
Glenthøj, Louise Birkedal
author_facet Gundersen, Kristina Ballestad
Rasmussen, Andreas Rosén
Sandström, Katharina Oravsky
Albert, Nikolai
Polari, Andrea
Ebdrup, Bjørn H
Nelson, Barnaby
Glenthøj, Louise Birkedal
author_sort Gundersen, Kristina Ballestad
collection PubMed
description INTRODUCTION: Schizotypal disorder is associated with a high level of disability at an individual level and high societal costs. However, clinical recommendations for the treatment of schizotypal disorder are scarce and based on limited evidence. This review aims to synthesise the current evidence on treatment for schizotypal disorder making recommendations for clinical practice. METHODS AND ANALYSIS: This systematic review protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A systematic literature search will be performed in PsychArticles, Embase, Medline and Cochrane Central Register of Controlled Trials. Additionally, we will search for relevant articles manually. Inclusion criteria are published studies including individuals diagnosed with schizotypal personality disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria, or schizotypal disorder according to International Classification of Diseases (ICD) criteria. We will include interventional studies comprising any pharmacological and non-pharmacological treatment trials for patients with schizotypal disorder, and all relevant outcome measures will be reported. Risk of bias will be assessed by Cochrane risk-of-bias tools. Data will be synthesised using narrative or thematic analysis and, if suitable, through meta-analysis. ETHICS AND DISSEMINATION: No original data will be collected as part of this study and ethics approval is, therefore, not applicable. The results will be disseminated through peer-reviewed publication and presented at international scientific meetings. We will aim at submitting the final paper for publication within 4 months of completion of analyses. Furthermore, this systematic review will inform clinicians and researchers on the current state of evidence on treatment for schizotypal disorder. Findings may guide proposals for further research and potentially guide recommendations for clinical practice using the Grading of Recommendations Assessment, Development and Evaluation. PROSPERO REGISTRATION NUMBER: CRD42022375001.
format Online
Article
Text
id pubmed-10660957
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-106609572023-11-17 Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice Gundersen, Kristina Ballestad Rasmussen, Andreas Rosén Sandström, Katharina Oravsky Albert, Nikolai Polari, Andrea Ebdrup, Bjørn H Nelson, Barnaby Glenthøj, Louise Birkedal BMJ Open Mental Health INTRODUCTION: Schizotypal disorder is associated with a high level of disability at an individual level and high societal costs. However, clinical recommendations for the treatment of schizotypal disorder are scarce and based on limited evidence. This review aims to synthesise the current evidence on treatment for schizotypal disorder making recommendations for clinical practice. METHODS AND ANALYSIS: This systematic review protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A systematic literature search will be performed in PsychArticles, Embase, Medline and Cochrane Central Register of Controlled Trials. Additionally, we will search for relevant articles manually. Inclusion criteria are published studies including individuals diagnosed with schizotypal personality disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria, or schizotypal disorder according to International Classification of Diseases (ICD) criteria. We will include interventional studies comprising any pharmacological and non-pharmacological treatment trials for patients with schizotypal disorder, and all relevant outcome measures will be reported. Risk of bias will be assessed by Cochrane risk-of-bias tools. Data will be synthesised using narrative or thematic analysis and, if suitable, through meta-analysis. ETHICS AND DISSEMINATION: No original data will be collected as part of this study and ethics approval is, therefore, not applicable. The results will be disseminated through peer-reviewed publication and presented at international scientific meetings. We will aim at submitting the final paper for publication within 4 months of completion of analyses. Furthermore, this systematic review will inform clinicians and researchers on the current state of evidence on treatment for schizotypal disorder. Findings may guide proposals for further research and potentially guide recommendations for clinical practice using the Grading of Recommendations Assessment, Development and Evaluation. PROSPERO REGISTRATION NUMBER: CRD42022375001. BMJ Publishing Group 2023-11-17 /pmc/articles/PMC10660957/ /pubmed/37977859 http://dx.doi.org/10.1136/bmjopen-2023-075140 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Mental Health
Gundersen, Kristina Ballestad
Rasmussen, Andreas Rosén
Sandström, Katharina Oravsky
Albert, Nikolai
Polari, Andrea
Ebdrup, Bjørn H
Nelson, Barnaby
Glenthøj, Louise Birkedal
Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice
title Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice
title_full Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice
title_fullStr Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice
title_full_unstemmed Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice
title_short Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice
title_sort treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice
topic Mental Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660957/
https://www.ncbi.nlm.nih.gov/pubmed/37977859
http://dx.doi.org/10.1136/bmjopen-2023-075140
work_keys_str_mv AT gundersenkristinaballestad treatmentofschizotypaldisorderaprotocolforasystematicreviewoftheevidenceandrecommendationsforclinicalpractice
AT rasmussenandreasrosen treatmentofschizotypaldisorderaprotocolforasystematicreviewoftheevidenceandrecommendationsforclinicalpractice
AT sandstromkatharinaoravsky treatmentofschizotypaldisorderaprotocolforasystematicreviewoftheevidenceandrecommendationsforclinicalpractice
AT albertnikolai treatmentofschizotypaldisorderaprotocolforasystematicreviewoftheevidenceandrecommendationsforclinicalpractice
AT polariandrea treatmentofschizotypaldisorderaprotocolforasystematicreviewoftheevidenceandrecommendationsforclinicalpractice
AT ebdrupbjørnh treatmentofschizotypaldisorderaprotocolforasystematicreviewoftheevidenceandrecommendationsforclinicalpractice
AT nelsonbarnaby treatmentofschizotypaldisorderaprotocolforasystematicreviewoftheevidenceandrecommendationsforclinicalpractice
AT glenthøjlouisebirkedal treatmentofschizotypaldisorderaprotocolforasystematicreviewoftheevidenceandrecommendationsforclinicalpractice